Similar Posts
The U.S. Healthcare System Is Back to Its High-Spending Ways
Shutterstock For a few years, U.S. healthcare spending seemed to be under control, rising no faster than the economy as a whole. The proportion of our GDP spent on healthcare was flatter than a Nebraska cornfield in November. Here’s how much we spent on healthcare, relative to the economy as a whole, between 2009 and…
Quote of the Day
“Blindness cuts us off from things, but deafness cuts us off from people.” – Helen Keller (Click to view comments)
Health Insurance Prices Declining under Obamacare
One year does not a trend make, but it does look like prices for health insurance under Obamacare next year will decline, on average. Ezra Klein, over at Vox.com, produced a nice picture of these prices: Who knows: in the long run, maybe the name of this law – The Affordable Care Act – will…
Repealing Obamacare Could Close Your Local Hospital
Shutterstock Last spring and summer, the Republicans stumbled in their efforts to repeal and replace Obamacare. But they might try a new approach later this year. If they do, expect to hear more debates about what their replacement plans mean for chronically ill Americans. People with pre-existing conditions might get priced out of insurance. People…
Do We Have a Drug Problem in the US?
Since the recession hit hard a few years ago, health care expenditures have slowed dramatically. It now looks like, at least for medications, cost increases are making a comeback. For instance: Nexium, a heartburn drug, had a 7.8% price hike to a $262 average prescription in the first nine months of 2012. Enough to make…
Breast Cancer Chemotherapy – Here Is What Happened When Outrageous Prices Met The Free Market
Nine to twelve years. That’s about how long most drug companies have to make serious money on new products before their patent protection ends. Then, generic companies enter the fray and prices, typically, plummet. Yet, two decades after coming to market, Herceptin (a drug used to treat breast and stomach cancer) was still priced at…